Drug Trial Radar · NCT05956626
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
51
Planned (sponsor's estimate)
Start
Aug 25, 2023
Primary completion
Sep 28, 2026
Study completion Sep 28, 2026
Sponsor
- Lead sponsor
- OcugenIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects). Phase 1 is complete and closed for enrollment. It was a multicenter, open-label, dose ranging/dose escalation study that enrolled 9 subjects. OCU410ST Phase 1- Retinal Structure and Visual Function Data Results * Safety: Favorable safety and tolerability profile No SAE deemed related to OCU410ST including intraocular inflammation, exudation, endophthalmitis, anterior ischemic optic neuropathy (AIONs) or vasculitis. * Primary Endpoint: Structural Improvement Atrophic lesions grew slower by 48% at 12M in evaluable treated eyes when compared to untreated eyes * Secondary Endpoint: Visual Function (BCVA) 100% evaluable treated eyes demonstrated stabilization or improvement when compared to untreated eyes in visual function OCU410ST Phase 1- Structural and Functional Outcomes at 12M Data Results * The GARDian3 clinical trial for ABCA4- related retinopathies including Stargardt disease builds upon encouraging results and positive data from the Phase 1 GARDian trial, which demonstrated 48% slower lesion growth at 12-month follow-up in evaluable treated eyes compared to untreated eyes * Additionally, evaluable treated eyes showed a statistically significant (p=0.031) and clinically meaningful improvement of nearly 2-line/9-letter gain in best corrected visual acuity (BCVA) at 12-month follow-up when compared to untreated eyes.
Conditions
- Stargardt Disease
Interventions
OCU410STDrug
Subretinal Administration of OCU410ST
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in atrophic lesion size as measured by Fundus Auto FluorescenceTime frame: 12 months (Screening to 12 months post OCU410ST administration)
- Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events))Time frame: 12 months (Screening to 12 months post OCU410ST administration)
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Associated Retina Consultants
Phoenix, Arizona
Retinal Consultants Medical Group
Sacramento, California
Vitreo Retinal Associates, P.A.
Gainesville, Florida
Bascom Palmer Eye Institute
Miami, Florida
Advanced Research, LLC
Pompano Beach, Florida
Retina Partners Midwest, P.C.
Carmel, Indiana
Boston Children's Hospital
Boston, Massachusetts
Mississippi Retina Associates
Jackson, Mississippi
The Retina Institute
St Louis, Missouri
Duke Eye Center
Durham, North Carolina
Erie Retina Research, LLC
Erie, Pennsylvania
Retina Consultants of Texas
Bellaire, Texas
Retina Foundation of the Southwest
Dallas, Texas
Valley Retina Institute
McAllen, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.